Blog & Analysis #phispers #pharmaflow

This week, Phispers brings you news about two antidepressants — J&J’s esketamine and Allergan’s rapastinel. While J&J’s drug bagged FDA approval, rapastinel failed in phase III trials. With troubles looming large ove...

This week, Phispers brings you news about the sudden and unexpected resignation of the USFDA commissioner Scott Gottlieb, a day after his crackdown on retailers selling tobacco to young people. The other big news came from BMS and Celgene — t...

The world of pharmaceuticals witnessed considerable M&A activity over the last week. GE sold off its biopharma business to Danaher Corporation for US$ 21 billion. Roche bought Spark Therapeutics for US$ 4.8 billion, and Ipsen struck a US$ 1.3 b...

This week, Phispers brings you news about Israeli generic drug giant Teva, as it plans to close or divest 11 manufacturing sites in 2019 to reduce its cost and debt burden. India’s Serious Fraud Investigation Office has said the alleged fu...

Leading Indian companies, such as Dr Reddy’s Laboratories and Lupin Limited were issued a Form 483 by the US Food and Drug Administration’s (FDA) for deficiencies in their quality, production and equipment systems and poor handling o...

This week, Phispers brings you news about a reflection paper released by the International Council on Harmonization (ICH) that seeks to standardize generic drugs across borders. In the US, a federal jury has ordered Takeda to pay Bayer US$ 155.19...

The heparin adulteration scandal had engulfed the world of pharmaceuticals in 2008. Ten years on, the spotlight returned to drug manufacturing as millions of blood pressure (BP) medicines were recalled due to the risk of them containing potential ...

This week, Phispers brings you news on Mylan bagging an FDA nod for its generic version of GSK’s blockbuster asthma treatment Advair Diskus.  The agency also approved Evolus’ wrinkle treatment, which is expected to pose tough compet...

This week, Phispers brings you news about how the ongoing recalls of sartans are likely to worsen the shortage of blood pressure drugs in the US. In the UK, Big Pharma announced their plans for a no-deal Brexit, while Novartis raised an alarm over ...

In 2018, each month PharmaCompass published PharmaFlow — a compilation of all the major deals in the industry that took place in the preceding month. We begin 2019 with our annual compilation of the deals of 2018, packed with some exci...